Characterization and in vitro release of Periplaneta americana-loaded nanoparticles / 中草药

ABSTRACT

Objective: To prepare Periplaneta americana extract CII-3-loaded nanoparticles for oral administration, and to investigate the in vitro release profile of CII-3-loaded nanoparticles and the protection of nanoparticles for CII-3 extract in vitro. Methods: The in vitro release behavior of the CII-3-loaded nanoparticles was carried out in the artificial gastric juice, artificial intestinal juice, and pH 7.4 PBS, and the fitting of different models was performed based on the accumulative drug release percentages observed by Folin-reagent method; The amino acid content of CII-3 and CII-3-loaded nanoparticles at different time points in artificial gastric juice was determinated by ninhydrin colorimetry and degradation rates of the two drugs were compared. Results: The mean size of the resulted nanoparticles was about (109.9 ± 0.6) nm and the Zeta potential was (-37.5 ± 3.5) mV; The accumulative release level of CII-3-loaded nanoparticles Qt was (22.63 ± 1.17)% in the artificial gastric juice in the first 2 h, and then, in the artificial intestinal juice, the accumulative release level of CII-3-loaded nanoparticles over a period of 60 h was (72.35 ± 1.90)%, which was in line with Higuchi model release equations, Qt = 8.287 2 t1/2 + 7.758 6. The accumulative release level of CII-3-loaded nanoparticles was (72.67 ± 1.65)% over a period of 10 d, which was in line with Weibull equation, lnln[1/(1-Qt)] = 0.403 7 ln(t-0.411 9)-1.713 3; The CII-3 was completely degraded in 4 h in the artificial gastric juice, while about 70% of CII-3 contained in nanoparticles was degraded. Conclusion: CII-3-loaded nanoparticles have a satisfactory sustained in vitro release effect, and the stability of CII-3 contained in the nanoparticles is improved in the artificial gastric juice.